Chester County News and Community Website
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said it has resubmitted its biologics license application for MOLBREEVI to the U.S. Food and Drug Administration, a key regulatory step toward approval …
FDA Clock Restarts: Savara Refiles MOLBREEVI for Rare Lung Disease Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced the publication of a manuscript detailing long-term outcomes for molgramostim inhalation solution in patients with autoimmune pulmonary alveolar proteinosis (aPAP). The study, …
Savara Inc. Publishes Promising Long-Term Outcomes for aPAP Treatment Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI, a potential …
Savara Begins FDA Submission for Rare Lung Disease Treatment Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) recently featured in a new episode of The Balancing Act® on Lifetime TV, focusing on autoimmune Pulmonary Alveolar Proteinosis (aPAP). This episode, part …
Savara Inc. Shines Spotlight on Rare Lung Disease in New TV Feature Read More